These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18373706)

  • 41. Comparison of chromosomal rearrangements in bone marrow cells and blast transformed B-cells in relapse of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Andreieva SV; Korets KV; Ruzhinska OE; Skorokhod IM; Alkhimova OG
    Exp Oncol; 2017 Jul; 39(2):141-144. PubMed ID: 29483496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Elnair R; Ellithi M; Kallam A; Shostrom V; Bociek RG
    Ann Hematol; 2021 Oct; 100(10):2513-2519. PubMed ID: 34279675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mechanisms of cytopenia in chronic lymphoid leukemia: significance for prognosis].
    Najean Y; Deschrywer F
    Presse Med; 1986 Dec; 15(45):2231-4. PubMed ID: 2949252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway.
    Lenartova A; Randen U; Johannesen TB; Tjønnfjord GE
    Cancer Epidemiol; 2019 Jun; 60():128-133. PubMed ID: 30986631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Martínez-Trillos A; Pinyol M; Delgado J; Aymerich M; Rozman M; Baumann T; González-Díaz M; Hernández JM; Alcoceba M; Muntañola A; Terol MJ; Navarro B; Giné E; Jares P; Beà S; Navarro A; Colomer D; Nadeu F; Colado E; Payer AR; García-Cerecedo T; Puente XS; López-Otin C; Campo E; López-Guillermo A; Villamor N
    Leuk Lymphoma; 2018 Oct; 59(10):2318-2326. PubMed ID: 29115891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prevalence of ocular disease in chronic lymphocytic leukaemia.
    Buchan J; McKibbin M; Burton T
    Eye (Lond); 2003 Jan; 17(1):27-30. PubMed ID: 12579166
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.
    Molica S; De Rossi G; Luciani M; Levato D
    Haematologica; 1995; 80(2):176-93. PubMed ID: 7628755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
    Mauro FR; Foa R; Cerretti R; Giannarelli D; Coluzzi S; Mandelli F; Girelli G
    Blood; 2000 May; 95(9):2786-92. PubMed ID: 10779422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
    Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
    Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia.
    Ruchlemer R; Wotherspoon AC; Thompson JN; Swansbury JG; Matutes E; Catovsky D
    Br J Haematol; 2002 Sep; 118(4):952-8. PubMed ID: 12199772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival.
    Umit EG; Baysal M; Durmus Y; Demir AM
    Int J Lab Hematol; 2017 Oct; 39(5):552-556. PubMed ID: 28603911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
    Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD
    Br J Haematol; 2007 Nov; 139(3):398-404. PubMed ID: 17910629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases.
    Molica S; Brugiatelli M; Callea V; Morabito F; Levato D; Nobile F; Alberti A
    Eur J Haematol; 1994 Apr; 52(4):216-21. PubMed ID: 8005231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
    Xu J; Zhou P; Wang W; Sun A; Guo F
    J Mol Med (Berl); 2014 Jan; 92(1):77-92. PubMed ID: 24042463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.
    Catovsky D; Fooks J; Richards S
    Br J Haematol; 1989 Jun; 72(2):141-9. PubMed ID: 2757960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic lymphocytic leukemia in India--a clinico-hematological profile.
    Agrawal N; Naithani R; Mahapatra M; Panigrahi I; Kumar R; Pati HP; Saxena R; Choudhary VP
    Hematology; 2007 Jun; 12(3):229-33. PubMed ID: 17558698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    Wanquet A; Birsen R; Bonnet C; Boubaya M; Choquet S; Dupuis J; Lepretre S; Re D; Fahri J; Michallet AS; Ysebaert L; Lemal R; Lamy T; Delarue R; Troussard X; Cymbalista F; Levy V; Dietrich PY; Leblond V; Aurran-Schleinitz T
    Br J Haematol; 2017 Jan; 176(1):37-49. PubMed ID: 27858991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients.
    Geisler CH; Philip P; Christensen BE; Hou-Jensen K; Pedersen NT; Jensen OM; Thorling K; Andersen E; Birgens HS; Drivsholm A; Ellegaard J; Larsen JK; Plesner T; Brown P; Andersen PK; Hansen MM
    Leuk Res; 1997; 21(11-12):1011-23. PubMed ID: 9444933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.